Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2003
03/11/2003US6531139 Self-emulsifying formulation for lipophilic compounds
03/11/2003US6531128 Methods for treating glaucoma
03/11/2003US6531120 Comprising histamine, its receptor analog, serotonin and its receptor analog in an opthalmic solution or gel for reducing irritation due to infection, allergies, pollutants and other irritants in a pharmaceutically acceptable carrier
03/11/2003US6531117 Colloidal dispersion
03/11/2003US6531115 Analgesic and refreshing herbal composition and a process for preparing the same
03/11/2003US6531114 Sildenafil citrate chewing gum formulations and methods of using the same
03/11/2003US6530950 Intraluminal stent having coaxial polymer member
03/11/2003CA2421936A1 (2-azabicyclo[2.2.1]hept-7-yl)methanol derivatives as nicotinic acetylcholine receptor agonists
03/11/2003CA2346647C Treatment of dyspepsia
03/11/2003CA2264254C Phosphinic acid amides as matrix metalloprotease inhibitors
03/11/2003CA2254117C 2,4-diaminopyrimidine derivatives
03/11/2003CA2242351C Novel tricyclic compounds and drug compositions containing the same
03/11/2003CA2239422C Compositions, containing bismuth, for the prevention and treatment of gastrointestinal disorders
03/11/2003CA2146250C Process for preparing taxane derivatives
03/11/2003CA2146155C Process for preparing taxane derivatives
03/11/2003CA2121230C 1,3-dihydro-2h-imidazo(4,5-b) quinolin-2-one derivatives
03/11/2003CA2111375C Oral care compositions containing hop acids and method
03/11/2003CA2102187C Use of atipamezole for the treatment of male sexual impotence
03/11/2003CA2085605C Stimulation of hair growth with potassium channel openers and 5alpha-reductase inhibitors
03/11/2003CA2056793C 5-amino-5,6,7,8-tetrahydroquinolines and related compounds a process for their preparation and their use as medicaments
03/11/2003CA2041620C An ortho-lithiation process for the synthesis of 2-substituted-1-(tetrazol-5-yl) benzenes
03/11/2003CA2038416C Ascorbic acid derivatives
03/10/2003CA2401358A1 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
03/10/2003CA2401319A1 Use of statins to inhibit formation of osteoclasts
03/07/2003WO2002020481A2 Substituted 4-phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine
03/07/2003WO2002020472A1 Substituted phenylcyclohexane carboxylic acid amides and the use thereof
03/07/2003CA2421835A1 Substituted 4-phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridines
03/07/2003CA2421781A1 Substituted phenylcyclohexane carboxylic acid amides and the use thereof
03/06/2003WO2003019198A2 Methods relating to treatment of atherosclerosis
03/06/2003WO2003019196A2 Diagnosis and treatment of atherosclerosis
03/06/2003WO2003019144A2 METHODS AND COMPOSITIONS FOR SCREENING, DIAGNOSING, OR TREATING NF-λB RELATED DISEASE
03/06/2003WO2003018836A2 Model of autoimmune disease and methods for identifying agents against autoimmune disease
03/06/2003WO2003018817A1 Yeast membrane protein expression system and its application in drug screening
03/06/2003WO2003018799A2 Modulators of bone homeostasis identified in a high-throughput screen
03/06/2003WO2003018788A2 Improved nitroreductase enzymes
03/06/2003WO2003018770A2 Amplified oncogenes and their involvement in cancer
03/06/2003WO2003018768A2 Transmembrane protein differentially expressed in cancer
03/06/2003WO2003018755A2 Wild-type ras as a cancer therapeutic agent
03/06/2003WO2003018745A2 Method of screening for drug hypersensitivity reaction
03/06/2003WO2003018743A2 Emu-based formulations for wound treatment
03/06/2003WO2003018640A2 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
03/06/2003WO2003018639A1 Hyperbranched amylopectin for use in methods for surgical or therapeutic treatment of mammals or in diagnostic methods, especially for use as a plasma volume expander
03/06/2003WO2003018636A2 Chimaeric peptides of insulin, their compositions and use in treating diabetes
03/06/2003WO2003018626A2 Novel genetic products from ashbya gossypii, associated with the structure of the cell wall or the cytoskeleton
03/06/2003WO2003018603A1 Aminoglycoside lipid derivatives for transfection
03/06/2003WO2003018602A1 Ferrocene mannose derivatives activating the killing of intracellularly localised microorganisms
03/06/2003WO2003018595A2 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
03/06/2003WO2003018594A1 Targeted bisplatinum polyamines as pro-drugs: selective release of platinum
03/06/2003WO2003018591A1 Novel pseudolaric acid-b derivatives, their preparation and pharmaceutical compositions
03/06/2003WO2003018589A1 Novel 4-aminofuropyrimidines and the use thereof
03/06/2003WO2003018586A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease
03/06/2003WO2003018585A1 Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
03/06/2003WO2003018582A1 Novel imidazopyridine compounds with therapeutic effect
03/06/2003WO2003018581A1 1,2-dihydro-2-oxo-1,8-naphthyridine derivative
03/06/2003WO2003018580A1 Naphthyridine derivative
03/06/2003WO2003018579A1 Alkyne-aryl phosphodiesterase-4 inhibitors
03/06/2003WO2003018576A1 New piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity
03/06/2003WO2003018574A1 Rapamycin dialdehydes
03/06/2003WO2003018573A1 Rapamycin 29-enols
03/06/2003WO2003018568A2 Ascorbic acid derivatives, methods of synthesis and pharmaceutical use thereof
03/06/2003WO2003018566A1 New piperidinyl derivates as modulators of chemokine receptor activity
03/06/2003WO2003018564A1 Vascular wall-selective acat inhibitor
03/06/2003WO2003018563A1 Anti-inflammatory and protein kinase inhibitor composition and method of use
03/06/2003WO2003018561A1 N-type calcium channel antagonists for the treatment of pain
03/06/2003WO2003018560A1 N-type calcium channel antagonists for the treatment of pain
03/06/2003WO2003018557A1 Hydrazinopeptoids and their uses for treating cancers
03/06/2003WO2003018556A1 Piperidine derivatives useful as modulators of chemokine receptor activity
03/06/2003WO2003018553A1 Oral antidiabetic agents
03/06/2003WO2003018551A1 New mandelic acid derivatives and their use as thrombin inhibitors
03/06/2003WO2003018549A2 Bicyclic compounds as inhibitors of chemokine binding to us28
03/06/2003WO2003018545A1 24-sulfur-substituted analogs of 1α,25-dihydroxy vitamin d¿3?
03/06/2003WO2003018543A1 Novel cyclohexyl sulphones
03/06/2003WO2003018542A1 Novel norstatin derivative
03/06/2003WO2003018537A1 Antiviral protease inhibitors
03/06/2003WO2003018536A1 Chemotherapeutic agents
03/06/2003WO2003018535A2 Novel aminobenzoephenones
03/06/2003WO2003018529A1 Monounsaturated fatty acids of at least 20 carbon atoms and perhydrocyclopentanophenanthrene nucleus combination molecules and their use as weight-loss agents
03/06/2003WO2003018515A2 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
03/06/2003WO2003018135A1 Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
03/06/2003WO2003018134A2 Bioadhesive compositions and methods for enhanced mucosal drug absorption
03/06/2003WO2003018075A2 Transdermal therapeutic system with fentanyl or related substances
03/06/2003WO2003018071A1 Transdermal therapeutic system (tts) with fentanyl as active ingredient
03/06/2003WO2003018070A1 Stilbene derivatives and their use for binding and imaging amyloid plaques
03/06/2003WO2003018069A1 Preparation and diabetic use of gibberellins
03/06/2003WO2003018064A2 Lipophilic drug compositions
03/06/2003WO2003018062A1 Improved therapeutic protocols
03/06/2003WO2003018060A1 Composition for treating parkinson's disease containing a cb1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain
03/06/2003WO2003018059A2 Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
03/06/2003WO2003018058A1 Myocardial cell apoptosis inhibitors
03/06/2003WO2003018057A1 Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect
03/06/2003WO2003018045A1 A pharmaceutical being used for treating hiv infection, the composition and uses thereof
03/06/2003WO2003018043A1 Compositions and methods for treating subjects with hyperglycemia
03/06/2003WO2003018042A1 Compositions for treatment and prevention of cold having antiviral activity
03/06/2003WO2003018038A2 Composition for the treatment of varicose veins
03/06/2003WO2003018035A1 Pharmaceutical preparation for treating wounds
03/06/2003WO2003018033A1 Use of fucans in the treatment of adhesions, arthritis and psoriasis
03/06/2003WO2003018032A1 Antithrombotic compositions comprising low molecular weight heparin and low molecular weight dermatan sulphate
03/06/2003WO2003018031A2 Single dose azithromycin for treating respiratory infections
03/06/2003WO2003018030A1 Mutagenic nucleoside analogs for the treatment of viral disease
03/06/2003WO2003018029A1 Anti-bacterial agents based upon oxoanion binding
1 ... 5541 5542 5543 5544 5545 5546 5547 5548 5549 5550 5551 5552 5553 5554 5555 5556 5557 5558 5559 5560 5561 ... 7860